Literature DB >> 33002569

T cell immunity to hepatitis C virus: Lessons for a prophylactic vaccine.

Robert Thimme1.   

Abstract

There is consensus that HCV-specific T cells play a central role in the outcome (clearance vs. persistence) of acute infection and that they contribute to protection against the establishment of persistence after reinfection. However, these T cells often fail and the virus can persist, largely as a result of T cell exhaustion and the emergence of viral escape mutations. Importantly, HCV cure by direct-acting antivirals does not lead to a complete reversion of T cell exhaustion and thus HCV reinfections can occur. The current lack of detailed knowledge about the immunological determinants of viral clearance, persistence and protective immunity is a major roadblock to the development of a prophylactic T cell vaccine. This minireview highlights the basic concepts of successful T cell immunity, major mechanisms of T cell failure and how our understanding of these concepts can be translated into a prophylactic vaccine.
Copyright © 2020 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  HCV; Hepatitis C virus; Prohylactic vaccine; T cell exhaustion; T cells

Mesh:

Substances:

Year:  2020        PMID: 33002569     DOI: 10.1016/j.jhep.2020.09.022

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  17 in total

Review 1.  'Stem-like' precursors are the fount to sustain persistent CD8+ T cell responses.

Authors:  Dietmar Zehn; Robert Thimme; Enrico Lugli; Gustavo Pereira de Almeida; Annette Oxenius
Journal:  Nat Immunol       Date:  2022-05-27       Impact factor: 31.250

2.  Modified E2 Glycoprotein of Hepatitis C Virus Enhances Proinflammatory Cytokines and Protective Immune Response.

Authors:  Vijayamahantesh Vijayamahantesh; Tapas Patra; Keith Meyer; Mohamad-Gabriel Alameh; Erin K Reagan; Drew Weissman; Ranjit Ray
Journal:  J Virol       Date:  2022-05-25       Impact factor: 6.549

Review 3.  Hepatitis C virus: A critical approach to who really needs treatment.

Authors:  Elias Kouroumalis; Argyro Voumvouraki
Journal:  World J Hepatol       Date:  2022-01-27

Review 4.  [Development approaches for vaccines against hepatitis C virus infections].

Authors:  Dorothea Bankwitz; Thomas Krey; Thomas Pietschmann
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2022-01-11       Impact factor: 1.513

5.  Persistent RNA virus infection is short-lived at the single-cell level but leaves transcriptomic footprints.

Authors:  Peter Reuther; Katrin Martin; Mario Kreutzfeldt; Matias Ciancaglini; Florian Geier; Diego Calabrese; Doron Merkler; Daniel D Pinschewer
Journal:  J Exp Med       Date:  2021-08-16       Impact factor: 14.307

6.  Th1-Biased Hepatitis C Virus-Specific Follicular T Helper-Like Cells Effectively Support B Cells After Antiviral Therapy.

Authors:  Katharina Zoldan; Sabine Ehrlich; Saskia Killmer; Katharina Wild; Maike Smits; Marissa Russ; Anna-Maria Globig; Maike Hofmann; Robert Thimme; Tobias Boettler
Journal:  Front Immunol       Date:  2021-09-30       Impact factor: 7.561

7.  Hepatitis C virus DNA vaccines: a systematic review.

Authors:  Ali Shayeghpour; Roya Kianfar; Parastoo Hosseini; Mehdi Ajorloo; Sepehr Aghajanian; Mojtaba Hedayat Yaghoobi; Tayebeh Hashempour; Sayed-Hamidreza Mozhgani
Journal:  Virol J       Date:  2021-12-13       Impact factor: 4.099

Review 8.  Structure-Based and Rational Design of a Hepatitis C Virus Vaccine.

Authors:  Johnathan D Guest; Brian G Pierce
Journal:  Viruses       Date:  2021-05-05       Impact factor: 5.818

Review 9.  Mechanisms of Hepatitis C Virus Escape from Vaccine-Relevant Neutralizing Antibodies.

Authors:  Rodrigo Velázquez-Moctezuma; Elias H Augestad; Matteo Castelli; Christina Holmboe Olesen; Nicola Clementi; Massimo Clementi; Nicasio Mancini; Jannick Prentoe
Journal:  Vaccines (Basel)       Date:  2021-03-20

Review 10.  Where to Next? Research Directions after the First Hepatitis C Vaccine Efficacy Trial.

Authors:  Christopher C Phelps; Christopher M Walker; Jonathan R Honegger
Journal:  Viruses       Date:  2021-07-13       Impact factor: 5.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.